Newsletter | November 22, 2023

11.22.23 -- "Alice In [mRNA] Wonderland:" 3 Realities Facing The mRNA Industry

FEATURED EDITORIAL

“Alice In [mRNA] Wonderland:” 3 Realities Facing The mRNA Industry

By Anna Rose Welch, director, Cell & Gene Collaborative

The mRNA industry is an exciting place to be, and I have no doubt we will celebrate some significant triumphs in the future. But there are three critical realities (or perhaps difficult truths) I was reminded of during the mRNA Therapeutics Summit worth reiterating to keep us grounded through all our uninhibited dreaming.

Guidelines For mRNA Drug Product Manufacturing And Quality Control

By John F. Cipollo, United States Pharmacopeia

The lightning-fast rise of mRNA raised the need for manufacturing standards and consensus on product quality attributes and test methods. This article provides perspective and insight on PQAs for mRNA vaccines and other mRNA-based products.

4 Major Trends In Lipid Nanoparticle Research

By Alexander Aust and Abigael Frederick, Aust Business Solutions

When biopharmaceutical consultant Alexander Aust noticed a flood of new research on lipid and polymer nanoparticles pouring out of universities, he started collecting it. Soon, his collection grew enough to reveal trends in the research of nanoparticles in oncology, neurology, infectious disease, and, of course, nucleic acids. He provides a quick overview of those trends and the database with links to published research — more than 300 articles published since 2020.

INDUSTRY INSIGHTS

Efficient, Large-Scale Transfection Of T-Cells Using Flowfect Technology

White Paper | BioCentriq

The objective of this study was to test the transfection of T cells with GFP mRNA for the evaluation of cell viability, transfection efficiency, and post-transfection growth using Kytopen’s Flowfect technology.

End-To-End Solutions To Support Your mRNA Therapeutics Workflow

Infographic | Thermo Fisher Scientific Bioproduction

Take a step-by-step review of the mRNA therapeutics journey and find out how you can meet the critical process, scale, quality, and regulatory needs from development to commercialization.

Determining RNA Integrity And Purity By Capillary Gel Electrophoresis

Application Note | MilliporeSigma

To ensure mRNA product quality, it is important to confirm the integrity of the RNA. Examine the results of a study challenging the performance of the CGE method in assessing mRNA integrity and purity.

Oligonucleotide Manufacturing: How To Get A Strong Start

Article | By Lucy Cook, Ph.D., Cytiva

If you’re developing an antisense oligonucleotide, siRNA, or other oligonucleotide therapeutic, you’re aware of their potential. Explore five keys to success for oligo synthesis, scale-up, and manufacturing.

Drug Discovery And Screening, A Digital Era For RNA-LNP Therapeutics

Article | Precision NanoSystems

Learn about the key stages of drug discovery and screening, as well as how to overcome bottlenecks in screening mRNA-LNPs to rapidly develop genomic medicines.

mRNA/saRNA Manufacturing: RNA Therapeutic Delivery And Applications

Q&A | Aldevron

Venkata Indurthi, Ph.D., shares his knowledge and experience with manufacturing RNA, including insight into RNA delivery and the applications — present and future — that innovations in the field are enabling.

Evaluation Criteria Of Freezer Systems For Bulk Pharmaceuticals

Webinar | Entegris, Inc.

Review data and evidence that demonstrate the benefits of an integrated approach in achieving critical end-user goals, such as scalability, efficiency, sustainability, and optimizing process economics.